OptimizeRx Corp. (NASDAQ:OPRX) Receives $20.50 Average Target Price from Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $17.5714.

OPRX has been the subject of a number of research reports. Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 15th. B. Riley Financial reiterated a “buy” rating and issued a $11.00 price target (down from $28.00) on shares of OptimizeRx in a research report on Friday. Stephens dropped their price objective on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research note on Friday. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Finally, Citizens Jmp increased their target price on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday, November 7th.

Institutional Trading of OptimizeRx

A number of large investors have recently made changes to their positions in OPRX. Nisa Investment Advisors LLC raised its stake in OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx during the second quarter worth about $44,000. BNP Paribas Financial Markets raised its position in shares of OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after buying an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of OptimizeRx in the fourth quarter valued at approximately $62,000. Finally, USA Financial Formulas purchased a new position in shares of OptimizeRx during the third quarter valued at approximately $131,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Stock Down 10.5%

OptimizeRx stock opened at $6.74 on Wednesday. OptimizeRx has a fifty-two week low of $3.99 and a fifty-two week high of $22.25. The firm has a market capitalization of $125.63 million, a price-to-earnings ratio of 25.92 and a beta of 1.20. The stock’s fifty day moving average is $10.52 and its two-hundred day moving average is $14.73. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.05 and a current ratio of 3.05.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.81%. Analysts predict that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx declared that its board has authorized a share buyback program on Thursday, March 5th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Key OptimizeRx News

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.